Recent research shows that microRNAs (miRNAs) may be potential biomarkers of cancer. MiRNAs are noncoding RNA molecules that regulate gene expression in the post-transcriptional phase. When miRNA count is depleted, gene expression can become dysregulated, consequently leading to progression or drug resistance in cancer. Therefore, many researchers have begun to investigate the role of miRNA as a potential biomarker of cancer, and its role in targeted drug therapy. Artificial Intelligence has emerged as a recent breakthrough to identify cancer types with high accuracy. Even though cancer is a complex and extremely heterogeneous condition, the current practice of treating cancer -- which entails surgery, radiation therapy, chemotherapy, and immunotherapy -- is a one-size-fits-all approach that results in the prescription of the same drug for every patient with the same type and stage of cancer. This approach is expensive, time-consuming, causes the patients to suffer, and worse, prescribed cancer drugs are ineffective for 75% of the time. Machine learning can be used to deliver precision cancer therapeutics based on genomic profiles of patient's tumors.